Cheryl Guttman Krader, BS, Pharm

Patients are at risk for developing severe dry eye and ocular surface disease.

Developments in imaging, translational research and clinical trials of treatments for retinal diseases dominated discussion at the two-day Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 virtual conference.

Recent literature review reveals dearth of data, highlights need for more research.

According to investigators, the virtual reality option could overcome hurdles associated with reliance on a physical course.

Several recent cases demonstrate how advancements in planning, imaging and surgical approaches can enable positive outcomes in very young patients.

Confronting issues unique to aging may lead to better outcomes.

XIPERE, the first therapy utilising the suprachoroidal space, demonstrates rapid efficacy, durable benefit and favourable safety profile.

Swept-source optical coherence tomography angiography can detect eyes at risk of developing exudative disease.

Ex vivo experiment identifies potential benefit for supplementary oxygen.

Integration of spectral domain optical coherence tomography with ultra-wide field imaging can increase accurate detection of diabetic macular oedema and epiretinal membrane.

Ophthalmologists face challenges of drug delivery for retinal diseases.

Study of subjects with rare inherited form of AD shows increased retinal capillary perfusion during the presymptomatic stage.

Why investigators are recognising AMD as a disease spectrum rather than a single entity.

Retrospective review highlights the sustained efficacy of combination procedure.

Prospective randomised trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

Early identification, aggressive treatment critical; when to consider surgical intervention

Study shows routine use may improve patient management, guide procedure planning

Secondary outcome measures provide signals of efficacy